Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Targeting cytokines to inflammation sites

Article Abstract:

Research describes a fusion proein engineered with cytokine action to target sites of inflammation. The fusion protein uses the latency-associated protein of transforming growth factor-beta1, which is fused to interferon-beta at one of the protein terminals. Data indicate that the fusion protein is activated by cerebrospinal fluid or synovial fluid from patients with inflammatory diseases but not by serum samples.

Author: Adams, Gill, Vessillier, Sandrine, Dreja, Hanna, Chernajovsky, Yuti
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
United Kingdom, France, Drug therapy, Drug use, Transforming growth factors, Cytokines, Interferon beta

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun

Article Abstract:

A demonstration that knockdown of the basic-region leucine zipper protein, c-Jun, by a catalytic DNA molecule, Dz13, suppresses vascular permeability and transendothellal emigration of leukocytes in murine models of vascular permeability, inflammation, acute inflammation and rheumatoid arthritis is presented. Result is found to implicate c-Jun as a useful target for anti-inflammatory therapies.

Author: Fahmy, Roger G., Chesterman, Colin N., Khachigian, Levon M., Waldman, Alla, Zhang, Guishui, Mitchell, Ainslie, Tedla, Nicodemus, Cai, Hong, Geczy, Carolyn R., Perry, Michael
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Care and treatment, Cells, Cell permeability, Protein research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A genetic approach to inactivating chemokine receptors using a modified viral protein

Article Abstract:

Research describes the construction of the fusion protein, degrakine, which specifically inactivates chemokine receptors by redirecting the HIV-1 protein, Vpu, to degrade CD4 in the endoplasm reticulum through proteasome of the host.

Author: Coffield, V. McNeil, Jiang, Qi, Su, Lishan
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
Physiological aspects, CD4 lymphocytes, HIV antigens, Viral proteins, Chemokine receptors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Inflammation, Protein engineering, United States, Genetic aspects
Similar abstracts:
  • Abstracts: An enquiry into the relationship between activation and performance using saccadic eye movement parameters. A method of evaluating VDT screen layout by eye movement analysis
  • Abstracts: Forget the myths and get on with TQM - fast. Should the board of directors be involved in TQM? Duke Power integrates employee rewards with its business vision of excellence
  • Abstracts: CEO turnover after acquisitions: are bad bidders fired? Local does as local is: information content of the geography of individual investors' common stock investments
  • Abstracts: In vivo veritas. In vivo cancer targeting and imaging with semiconductor quantum dots. Human antibodies from immunized donors are protective against anthrax toxin in vivo
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.